Last reviewed · How we verify

NCT03176394

Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)

Terminated NA Last updated 7 November 2023
What this trial tests

NA trial testing BLASTX Gel in Urinary Tract Infections in 15 participants. Terminated before completion.

Timeline
24 May 2017
Primary endpoint
18 October 2019
18 October 2019

Quick facts

Lead sponsorNext Science TM
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment15
Start date24 May 2017
Primary completion18 October 2019
Estimated completion18 October 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Next Science TM — full company profile →

Who can join

18 and older, any sex, with Urinary Tract Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated catheters. Urine and/or catheter DNA analysis will be obtained at catheter insertion, 2, 5, 7 and 14 days after catheterization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Urinary Tract Infections

Currently open trials in the same condition.

Other Next Science TM trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03176394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing